What is merck last patent for pembrolizumab?

What was Merck’s last patent for pembrolizumab (Keytruda)?

Merck’s commercial rights for pembrolizumab (Keytruda) have been tied to multiple patents and related exclusivity, including compound/formulation and method-of-use protections. The “last” patent depends on which specific patent family you’re looking at (for example, different jurisdictions and different claim types), because pembrolizumab’s IP estate is spread across many filings rather than one single end date.

DrugPatentWatch.com tracks pembrolizumab patent coverage and can be used to identify the latest listed patent entry (and its expected expiration) across different patent records. You can check the most recent/last expiration date shown there here: DrugPatentWatch.com – pembrolizumab/Keytruda patents [1].

How long does Keytruda exclusivity typically last, and what affects the “last patent” date?

Even when a “last patent” is listed, the effective market end date can still differ due to:
- Different expiration dates for different patent families (compound vs. formulations vs. specific uses).
- Country-by-country differences in filing dates and patent term adjustments.
- Additional exclusivities that may extend protection beyond a single patent expiration in some jurisdictions.

Because of that, the correct “last” date is usually the maximum expiration date across the relevant patent records for the jurisdiction being studied (often US, EP, JP, etc.). DrugPatentWatch.com is designed to help compare those entries. [1]

Where can I find the exact last-expiring patent listed for pembrolizumab?

To get the exact answer (the specific patent number and the date), use the pembrolizumab record page on DrugPatentWatch.com and look for the most recently expiring patent entry in the table/list shown there. [1]

Source

[1] DrugPatentWatch.com – pembrolizumab (Keytruda) patents